down arrow

enGene Holdings, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA29286M1059
USD
8.69
0.52 (6.36%)

Dec 19

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

7.898.89

52 Week

2.6511.14
Valuation
Technical
Day's Volume

CASH

206.83 k

Shareholding (Apr 2025)

FII

24.17%

Held by 17 FIIs

DII

28.1%

Held by 11 DIIs

Promoter

42.61%

What does enGene Holdings, Inc. do?

22-Jun-2025

enGene Holdings, Inc. is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, with no dividend yield and significant negative debt equity and return on equity metrics.

Overview: enGene Holdings, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>Financial Snapshot: Market cap: Micro Cap.<BR><BR>Key Metrics: Industry: Pharmaceuticals & Biotechnology, Dividend Yield: 0.00%, Debt Equity: -999,999.00, Return on Equity: -999,999.00%, Price to Book: 0.00.<BR><BR>Contact Details: Not available.

Read More

Is enGene Holdings, Inc. technically bullish or bearish?

20-Sep-2025

As of June 25, 2025, enGene Holdings, Inc. shows a mildly bearish trend with mixed indicators, having outperformed the S&P 500 in the short term but underperformed over the past year.

As of 25 June 2025, the technical trend for enGene Holdings, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a mix of indicators. The MACD is bullish on the weekly timeframe but bearish on the monthly, while the RSI shows bearish momentum on the weekly and no signal on the monthly. Moving averages are mildly bearish on the daily, and Bollinger Bands indicate a mildly bearish trend on the monthly. However, Dow Theory and OBV are both mildly bullish on the weekly and monthly, suggesting some underlying strength.<BR><BR>In terms of performance, enGene has outperformed the S&P 500 over the past week and month, with returns of 14.85% and 87.1%, respectively, compared to 1.05% and 2.33% for the index. However, over the longer term, the stock has underperformed, with a 1-year return of -4.26% versus 17.14% for the S&P 500.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 278 Million ()

stock-summary
P/E

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.85

stock-summary
Return on Equity

-999,999.00%

stock-summary
Price to Book

1.22

Revenue and Profits:
Net Sales:
(Quarterly Results - Apr 2025)
Net Profit:
-26 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
27.42%
0%
27.42%
6 Months
164.13%
0%
164.13%
1 Year
45.81%
0%
45.81%
2 Years
16.18%
0%
16.18%
3 Years
-15.3%
0%
-15.3%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

enGene Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-609.12%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
EV to EBIT
EV to EBITDA
EV to Capital Employed
EV to Sales
PEG Ratio
NA
Dividend Yield
ROCE (Latest)
ROE (Latest)
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Apr 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 7 Schemes (5.12%)

Foreign Institutions

Held by 17 Foreign Institutions (24.17%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by enGene Holdings, Inc."
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Oct'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Oct'24",
        "Oct'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-62.00",
          "val2": "-25.90",
          "chgp": "-139.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.80",
          "val2": "5.00",
          "chgp": "-44.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.40",
          "val2": "-69.90",
          "chgp": "99.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-55.10",
          "val2": "-99.90",
          "chgp": "44.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Oct'24stock-summary
Oct'24
Oct'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-62.00
-25.90
-139.38%
Interest
2.80
5.00
-44.00%
Exceptional Items
-0.40
-69.90
99.43%
Consolidate Net Profit
-55.10
-99.90
44.84%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

Not Applicable: The company has declared_date for only one period

Consolidated Net Profit

Not Applicable: The company has declared_date for only one period

All Annual Resultsstock-summary
stock-summaryCompany CV
About enGene Holdings, Inc. stock-summary
stock-summary
enGene Holdings, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."